Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a rapid and accurate spectrophotometric method using diazotized sulfanilic acid to measure minoxidil in both pharmaceutical formulations and pure form, demonstrating high precision and linearity within a concentration range of 5-40 μg/ml.

This study observed that patients with AA showed a high willingness to trade off lifespan for better disease-specific quality of life, indicating a significant disease burden.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

In this study, nail changes, particularly pitting, were associated with moderate to severe cases of alopecia areata and a positive family history, highlighting potential genetic factors in the condition.

This prospective observational study investigated 200 patients with non-scarring alopecia, concluding that accurate classification combined with individualized treatment, including combination therapies, significantly improved outcomes over monotherapy with topical minoxidil.

In this study, the combination of petroleum ether extracts from Jacquinia ruscifolia flowers and Thuja orientalis strobili demonstrated synergistic larvicidal effects against third-instar Culex quinquefasciatus larvae, achieving 100% mortality at 250 ppm with noted synergism particularly in a 1:2 ratio.

In this study, researchers observed that individuals with alopecia areata exhibited significant changes in scalp microbiota diversity and composition, which were linked to disease severity and inflammation markers, though it remains unclear if these microbial shifts are a cause or a result of hair loss.

In this cross-sectional study conducted at Farhat Hached Hospital in Tunisia, more than half of the 60 alopecia areata patients surveyed experienced depression, particularly younger individuals and those with severe or specific forms of the condition, underscoring the need for psychological support.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

In this case report, a patient with severe erythrodermic psoriasis and diffuse alopecia who was unresponsive to conventional treatments showed complete resolution of skin lesions and alopecia after being treated with ixekizumab.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.

In this study, Derma Genie™-H001 was shown to reduce inflammation, counteract oxidative and UVB-induced damage, and support hair growth-related gene expression in human dermal papilla cells, suggesting its potential as a functional cosmetic ingredient to alleviate hair loss symptoms.

In this study, an 18-year-old boy with alopecia areata successfully experienced normal and healthy hair regrowth after 4 months using microneedling with cupping, alongside internal herbal medication and topical oil application, as a cost-effective and less invasive alternative to high-cost hair treatments and transplantation.

This study optimized the extraction process for abomasum protein from Tianshan red deer, identifying two proteins with anti-inflammatory and anti-tumor activities, suggesting they could be beneficial in foods and nutraceuticals.

In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.

This study found that IL-4 VNTR intron 3 and TNF-α (rs1799964) gene polymorphisms do not have a significant association with alopecia areata susceptibility in the Egyptian population.

This study found that clobetasol propionate 0.05% was significantly more effective in stimulating hair re-growth in alopecia areata patients compared to topical tacrolimus 0.1%, with an excellent response observed in 74.3% of the clobetasol group versus 40% in the tacrolimus group.

This study found that expressions of TLR-3, TLR-7, TLR-8, and TLR-9 were significantly higher in alopecia areata patients compared to healthy controls, indicating a potential role in disease autoimmunity.

This study reports that carbamazepine can self-assemble into stable channel structures without guest polymers, while griseofulvin relies on guest molecules for structural stability in drug-polymer inclusion complexes.

This study investigated the molecular mechanisms behind the formation of drug-polymer inclusion complexes and found that carbamazepine can self-assemble into stable channel structures without guest polymers, unlike griseofulvin, which requires guest molecules for structural stability.

This research elucidates the molecular mechanisms underlying carbamazepine and griseofulvin's inclusion complex channel formations with polymers, revealing why carbamazepine forms stable channels independently, while griseofulvin requires polymeric support due to weaker interactions.

This source outlines the autoimmune condition alopecia areata, discussing its unclear etiology, the significant psychological impact despite not being life-threatening, and the challenging nature of its treatment, which varies greatly among individuals. The article summarizes disease pathogenesis, prevention, and treatment options.

The study observed that consuming Pflorida soup, made from UV-exposed oyster mushrooms, maintained significant vitamin D levels comparable to recommended daily intake, despite storage and cooking reducing the vitamin content.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

In patients with alopecia areata, this study found elevated levels of venous thromboembolism markers SFMC and F1 + 2 compared to healthy controls, potentially indicating an increased risk for this condition.

This study concluded that age is a significant risk factor for hair fall, as older age increases the likelihood of developing male pattern baldness among adults.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

This report describes a 17-year-old woman who experienced severe anagen effluvium after DRESS syndrome but achieved full recovery in two months with topical minoxidil.